The release of the data comes on the heels of a publication in Cell showing that therapeutic miRNA delivery could suppress tumorigenesis in a mouse model of liver cancer, which Mirna's CEO said bolsters the company's strategy.
The firm launched three microRNA-based tests during the fourth quarter, and posted a profit due to a capital gain on the sale of Auction Rate Securities to Credit Suisse. However, Rosetta only has enough cash to fund operations through mid-2010 and said that it may seek to raise additional funds.
An Affy spokesperson said the firm's interest in the market is an extension of its gene-expression profiling play, and said several "key advantages" over rival tools could enable it to profit in the market, which is poised to grow 25 percent through 2015.
The company is looking to differentiate itself from other players in the miRNA array market — such as Agilent Technologies, Life Technologies, Exiqon, and Febit — by stressing the "quality, performance, and affordability" of its OneArray platform.